Our Website is located at http://www.Nanoviricides.com. The Company has developed several anti-coronavirus drug candidates. Also it was found that SARS-CoV antibodies were cross-reacting with SARS-CoV-2. & The symptoms are generally less severe than SARS-CoV-2 but are similar. The nanoviricide is designed to protect the payload from metabolism in circulation. This increase may lead to increased effectiveness if there are no adverse effects. As of June 30, 2020, the Company has drawn down $1.1 million on this loan. No warrants were issued in this Offering. Anil Diwan on Fox Business - 01/28/2020”. & This may be one of the reasons why many antiviral antibodies fail in the field use. Also, the virus-binding ligands are chemically attached to the polymer. Expansion to additional indications is likely, as we perform further studies. Thus, HSV-1 primarily affects skin and mucous membranes causing “cold sores”. These studies established this drug candidate as a viable, effective potential drug. VZV is restricted to human tissue and only infects and replicates in human tissue. Intravenous acyclovir is also employed for treatment of various VZV indications. In some indications, the treatment has been continued for a year or so. At present we have not applied for any grants for these programs. & To date, the Company does not have any commercialized products. As such we assume that these datasets will be sufficient for filing an IND. & The current market size for anti-HIV treatments is in excess of $20 billion. There was no amendment to the license contract effected for this purpose. & The licenses can revert only in the case of a default by NanoViricides. Our ability to be competitive will depend on the success of this strategy. & The Company believes that our drugs by themselves may be eligible for patent protection. 2029(estimated) & Applications are in various prosecution stages. All of the resulting patents have substantially broad claims. & The facility became substantially operational at the end of December& 2015. Foscarnet is also used for VZV and ARN, but its toxicity is high. It is an influenza endonuclease inhibitor. The FDA may grant deferrals for submission of data, or full or partial waivers. We have never received approval for a product in the European Union to date. & Some of the PRVs have been “sold” for as much as $250M or so recently. & The Zika virus was added to this list recently. & This work-plan is expected to reduce certain risks of drug development. AR Biosystems,& Inc., Odessa, FL (non-GLP studies) & 2. In January& 2016, we signed an agreement with CORL. The H129 strain will be used in subsequent animal testing of nanoviricides. He is now Professor at Roseman University of Health Sciences College of Medicine, NV. A definitive agreement is expected to be negotiated between the parties thereafter. At June& 30, 2020, $561,580 was due to TheraCour. & Upon entry into the agreement additional deferrals ceased. The remaining deferred payments will become due upon IND filing. Website & Our website address is www.nanoviricides.com. & There are specific FDA regulations that govern this process. & These may not take into account all of the activities involved for the development. Our relationship with TheraCour is discussed below. All other consultant/contractors would be more readily replaceable. We currently depend upon the efforts and abilities of our management team. Their patient benefit profiles